Qurient Co. Ltd Asset Resilience Ratio
Qurient Co. Ltd asset resilience ratio. Qurient Co. Ltd (115180) has an Asset Resilience Ratio of 71.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 115180 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Qurient Co. Ltd (2016–2025)
Asset resilience ratio of Qurient Co. Ltd from 2016 to 2025. This chart shows how Qurient Co. Ltd's Asset Resilience Ratio has changed over time. Read 115180 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Qurient Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Qurient Co. Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩32.45 Billion | 71.23% |
| Total Liquid Assets | ₩32.45 Billion | 71.23% |
Asset Resilience Insights
- Very High Liquidity: Qurient Co. Ltd maintains exceptional liquid asset reserves at 71.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Qurient Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Qurient Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Qurient Co. Ltd Asset Resilience Ratio by Year (2016–2025)
Qurient Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Qurient Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.80% | ₩29.02 Billion ≈ $19.66 Million |
₩61.99 Billion ≈ $42.01 Million |
-23.82pp |
| 2024-12-31 | 70.62% | ₩46.31 Billion ≈ $31.38 Million |
₩65.57 Billion ≈ $44.44 Million |
-7.24pp |
| 2023-12-31 | 77.86% | ₩40.88 Billion ≈ $27.70 Million |
₩52.50 Billion ≈ $35.58 Million |
+9.74pp |
| 2022-12-31 | 68.12% | ₩26.17 Billion ≈ $17.73 Million |
₩38.41 Billion ≈ $26.03 Million |
+10.09pp |
| 2021-12-31 | 58.03% | ₩33.44 Billion ≈ $22.66 Million |
₩57.62 Billion ≈ $39.05 Million |
-22.76pp |
| 2018-12-31 | 80.80% | ₩34.90 Billion ≈ $23.65 Million |
₩43.20 Billion ≈ $29.27 Million |
+17.69pp |
| 2017-12-31 | 63.10% | ₩9.89 Billion ≈ $6.70 Million |
₩15.68 Billion ≈ $10.62 Million |
+55.48pp |
| 2016-12-31 | 7.62% | ₩2.00 Billion ≈ $1.36 Million |
₩26.24 Billion ≈ $17.78 Million |
-- |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more